Meifeng Tu

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 671 citations · Full text

A safe and potent anti-CD19 CAR T cell therapy

Zhitao Ying, Xue F. Huang, Xiaoyu Xiang et al. · Nature Medicine · 2019 · 435 citations · Full text

Cell Therapy, Immunology, Autoimmunity +2

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Li Yu, Meifeng Tu, Jörge E. Cortes et al. · Blood · 2017 · 171 citations · Full text

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma

Zhitao Ying, Ting He, Xiaopei Wang et al. · Molecular Therapy — Oncolytics · 2019 · 163 citations · Full text

Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin

Lijuan Deng, Yuqin Song, Ken H. Young et al. · Oncotarget · 2015 · 95 citations · Full text